NY-DELOS
11.5.2020 15:17:07 CEST | Business Wire | Press release
In response to the coronavirus pandemic, Delos, a wellness real estate and technology company, has formed a collaboration with Humanity 2.0 Well Being and the Pontifical Orientale Institute to upgrade the Vatican’s Orientale’s residences with its evidence-based health and wellness technologies and solutions.
Rome and the Vatican are slowly emerging from lockdown, providing a critical window to help build health resilience, prevent disease and reduce viral transmission in houses, offices, parishes and school facilities through scientifically-supported technologies and solutions.
Delos, the trusted scientific authority on healthy buildings, has customized a program for the Pontifical Orientale Institute, which includes air purification and surface cleaning technology, circadian lighting and other evidence-based interventions designed to help support immune health, reduce stress, improve sleep quality and promote overall well-being.
In partnership with Humanity 2.0 Well Being, the wellness platform created in collaboration with the Vatican (Holy See), the Pontifical Orientale Institute was identified due to its rich history and innovative leadership, as well as vital role in convening global interfaith groups at the Vatican. Led by Rev. David Nazar, S.J, the Pontifical Oriental Institute was created by Pope Benedict XV in 1917, and is currently a school of higher studies that has as its particular mission the service of the Oriental Churches.
“The Catholic Church runs the largest governmental school system in the world, serving in over 100 countries - some over 1,000 years old - and runs one-quarter of the world's health care institutions,” said Father David Nazar, Rector of the Orientale. “Its preoccupation has always been the care of the entire person and of society. Recent information technology and wellness sciences have brought to the fore much needed insights into humanizing the educational environment. Our students come from over 40 countries, many without deep resources, and student depression is an increasing phenomenon in a world that is struggling to find a common purpose. COVID-19 has shown us how fragile we are. With Delos and Humanity 2.0 Well Being, we will be implementing health and wellness tools that address these contemporary educational challenges, helping us continue our focus on strengthening the whole person- body, mind, and spirit. Pope Francis, with his focus on human ecology, has asked church institutions to show leadership. With Delos and Humanity 2.0 Well Being, the Orientale is doing just that.”
“We are honored to have been asked to customize our suite of research and technology solutions accrued over years into a first-of-its-kind program for the Pontifical Orientale Institute residences at this pivotal time,” said Paul Scialla, Founder and CEO of Delos. “We know that buildings have a profound impact on human health, but the current pandemic has magnified the essential need for evidence-based health interventions in the indoor environment, which are being shared with the Vatican and its global network.”
Given the Catholic Church’s global footprint, comprising 200,000 colleges, universities and other schools, 220,000 parishes, 117,000 nursing home and senior living facilities, and 10,000 orphanages in 196 countries, Delos’ Vatican program at the Orientale will be made available more widely to the Catholic Church to educate and shape institutional best practices.
“Through upgrading our educational buildings with health innovations, we are actually building human capacity at one of its most formative periods,” said Morad Fareed, CEO of Humanity 2.0 Well Being and a co-founder of Delos. “Father Nazar and the Orientale have a heritage as pioneers, and this initial partnership is both a template and a catalyst for greater strategic collaboration with the Vatican at this defining time.”
With the support of Pope Francis, and in conjunction with Fr. William Watson, S.J., vice president for advancement for the Orientale, the Orientale’s residences, offices, classrooms and library/conference facilities were significantly upgraded in 2017- the 100th anniversary of the Institute. These same residences will now become the first residences in the Vatican to implement Delos’ technologies and solutions.
The collaboration with Delos and Humanity 2.0 Well Being is advanced by the Orientale’s initiative to upgrade the technology infrastructure for all Orientale classrooms to enable the most comprehensive distance learning capabilities of any papal university, made possible through partnership with UBS partners James Mallahan and Mark Russo.
Delos is the founder of the International WELL Building Institute (IWBI), which created the WELL Building Standard™, currently being implemented in over 4,000 projects, surpassing 500 million square feet of wellness real estate in 61 countries. IWBI recently established a Task Force on Covid-19 and other respiratory infections - Co-Chaired by 17th Surgeon General of the United States Richard Carmona, Former Robert Wood Johnson Foundation President and CEO Dr. Risa Lavizzo-Mourey, UCLA’s Dr. Jonathan Fielding, and Harvard School of Public Health’s Joseph Allen – to advance the role of buildings in protecting and enhancing health.
About Delos
Delos is a wellness real estate and technology company with a mission to be the world’s leading catalyst for improving the health and well-being of people by improving the indoor environments where they live, work, sleep and play. Informed by more than seven years of research and rigorous analysis of environmental health impacts on people, Delos and its subsidiaries offer an array of evidence-based technology and solutions for the built environment. Delos is the founder of the International WELL Building Institute and the WELL Building Standard, the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that support and advance human health and wellness. The International WELL Building Institute administers and continues WELL’s development and drives market adoption. Delos collaborated with the Mayo Clinic to create the Well Living Lab, a scientific research center that uses exclusively human-centered research to understand the interaction between health and well-being and indoor environments. The company’s advisory board is comprised of leading professionals across real estate, healthcare, government policy and sustainability, including the 17th Surgeon General of the United States Richard Carmona, UCLA’s Dr. Jonathan Fielding, renowned wellness luminary Deepak Chopra, and sustainability advocate Leonardo DiCaprio. For more information about Delos, please visit www.delos.com
.
About Humanity 2.0 Well-Being
Humanity 2.0 was created to facilitate collaborative ventures between the historically siloed public, private, and faith-based sectors. Founded in 2018 in collaboration with the Dicastery for Integral Human Development at the Holy See (Vatican) led by His Eminence Cardinal Peter Turkson, the Humanity 2.0 Foundation has become a unique global force in its novel ability to identify important global initiatives, forge partnerships, and introduce scientific solutions for global impact. After two years of convenings in Vatican City with global luminaries from Ethics, Science, Health, and Technology, Humanity 2.0 Well Being was developed to focus more concretely on installing the world’s leading environmental and maternal wellness solutions throughout the Faith Sector and beyond. https://humanity2-0.org/
About the Pontifical Orientale Institute
The Mission of the Orientale is to pursue research, teaching, and publishing relating to the traditions of the Eastern Churches – a geography spanning from Russia to Ethiopia and from Italy to India - in their theology, liturgies, patristics, history, canon law, literature and languages, spirituality, archeology, and questions of ecumenical and geopolitical importance. The areas of primary concern today to the Orientale are the Middle East and the post-Soviet world. For more information about the Orientale, please visit https://orientale.it/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200511005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
